110 related articles for article (PubMed ID: 14506658)
21. Lymphocytes with a CD4+ CD8- CD3- phenotype are effectors of experimental cutaneous graft-versus-host disease.
Sakamoto H; Michaelson J; Jones WK; Bhan AK; Abhyankar S; Silverstein M; Golan DE; Burakoff SJ; Ferrara JL
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10890-4. PubMed ID: 1835792
[TBL] [Abstract][Full Text] [Related]
22. Immunodominant CD4+ T cell receptor Vbeta repertoires involved in graft-versus-host disease responses to minor histocompatibility antigens.
Berger MA; Korngold R
J Immunol; 1997 Jul; 159(1):77-85. PubMed ID: 9200441
[TBL] [Abstract][Full Text] [Related]
23. Target cells in graft-versus-host disease: implications for cancer therapy.
Murphy GF
Clin Rev Allergy Immunol; 2007 Oct; 33(1-2):113-23. PubMed ID: 18094950
[TBL] [Abstract][Full Text] [Related]
24. Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease.
Du W; Leigh ND; Bian G; O'Neill RE; Mei L; Qiu J; Chen GL; Hahn T; Liu H; McCarthy PL; Cao X
J Immunol; 2015 Nov; 195(9):4514-23. PubMed ID: 26392464
[TBL] [Abstract][Full Text] [Related]
25. Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease.
Rotolo JA; Stancevic B; Lu SX; Zhang J; Suh D; King CG; Kappel LW; Murphy GF; Liu C; Fuks Z; van den Brink MR; Kolesnick R
Blood; 2009 Oct; 114(17):3693-706. PubMed ID: 19666872
[TBL] [Abstract][Full Text] [Related]
26. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
27. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA
J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270
[TBL] [Abstract][Full Text] [Related]
28. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
29. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
[TBL] [Abstract][Full Text] [Related]
30. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
[TBL] [Abstract][Full Text] [Related]
31. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses.
Korngold R; Marini JC; de Baca ME; Murphy GF; Giles-Komar J
Biol Blood Marrow Transplant; 2003 May; 9(5):292-303. PubMed ID: 12766879
[TBL] [Abstract][Full Text] [Related]
32. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.
Jones SC; Murphy GF; Friedman TM; Korngold R
J Clin Invest; 2003 Dec; 112(12):1880-6. PubMed ID: 14679183
[TBL] [Abstract][Full Text] [Related]
33. Significance of selectively targeted apoptotic rete cells in graft-versus-host disease.
Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Jun; 10(6):357-65. PubMed ID: 15148489
[TBL] [Abstract][Full Text] [Related]
34. Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions.
Hartmann N; Messmann JJ; Leithäuser F; Weiswange M; Kluge M; Fricke H; Debatin KM; Strauss G
Blood; 2013 Jan; 121(3):556-65. PubMed ID: 23203823
[TBL] [Abstract][Full Text] [Related]
35. Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
Askew D; Zhou L; Wu C; Chen G; Gilliam AC
J Invest Dermatol; 2007 Aug; 127(8):1905-14. PubMed ID: 17429441
[TBL] [Abstract][Full Text] [Related]
36. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
[TBL] [Abstract][Full Text] [Related]
37. Acute graft-versus-host disease does not require alloantigen expression on host epithelium.
Teshima T; Ordemann R; Reddy P; Gagin S; Liu C; Cooke KR; Ferrara JL
Nat Med; 2002 Jun; 8(6):575-81. PubMed ID: 12042807
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-1 or tumor necrosis factor-alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice.
Vallera DA; Taylor PA; Vannice JL; Panoskaltsis-Mortari A; Blazar BR
Transplantation; 1995 Dec; 60(11):1371-4. PubMed ID: 8525541
[TBL] [Abstract][Full Text] [Related]
39. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.
Graubert TA; DiPersio JF; Russell JH; Ley TJ
J Clin Invest; 1997 Aug; 100(4):904-11. PubMed ID: 9259590
[TBL] [Abstract][Full Text] [Related]
40. Oligoclonal expansion of T cell receptor V beta 2 and 3 cells in the livers of mice with graft-versus-host disease.
Chen W; Howell CD
Hepatology; 2002 Jan; 35(1):23-9. PubMed ID: 11786956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
